<p>红鹤财富管理公司在第四季度购买了安进公司（NASDAQ:AMGN - 免费报告）股票的新头寸，根据其最近向证券交易委员会提交的 13F 文件。该基金购买了 1,975 股这家医疗研究公司的股票，价值约为 515,000 美元。</p>
<ul>
<li>MarketBeat 周报 – 12/2 - 12/6</li>
</ul>
<p>其他机构投资者和对冲基金最近也增加或减少了对该公司的持股。Talbot Financial LLC 在第四季度将其在安进的股份增加了 5.6%。Talbot Financial LLC 现在拥有 42,791 股这家医疗研究公司的股票，价值 11,153,000 美元，此前在此期间又购买了 2,274 股。瑞士国家银行在第三季度将其在安进的持股增加了 0.3%。瑞士国家银行现在拥有 1,592,233 股这家医疗研究公司的股票，价值 513,033,000 美元，此前在此期间又购买了 5,500 股。资产顾问投资管理公司在第三季度将其在安进的持股增加了 9.0%。资产顾问投资管理公司现在拥有 35,934 股这家医疗研究公司的股票，价值 11,578,000 美元，此前在上个季度又购买了 2,954 股。Principal Financial Group Inc.在第三季度将其在安进的持股增加了 6.0%。Principal Financial Group Inc.现在拥有 635,172 股这家医疗研究公司的股票，价值 204,659,000 美元，此前在此期间又购买了 35,785 股。最后，Ascent Wealth Partners LLC 在第四季度将其在安进的持股增加了 0.7%。Ascent Wealth Partners LLC 现在拥有 9,024 股这家医疗研究公司的股票，价值 2,352,000 美元，此前在上个季度又购买了 64 股。76.50% 的股票由机构投资者持有。</p>
<h2>分析师评级变动</h2>
<p>安进一直是多份研究报告的主题。杰富瑞金融集团在 11 月 12 日的研究报告中重申了对安进的 “买入” 评级，并给出了 380.00 美元的目标价。沃尔夫研究在 11 月 15 日的研究报告中开始覆盖安进，并对该股票给予了 “同行表现” 的评级。Redburn Partners 在 11 月 27 日的报告中将安进的目标价从 200.00 美元下调至 195.00 美元。花旗集团在 2 月 5 日的报告中重申了对安进的 “中性” 评级。最后，瑞银集团在 2 月 12 日的报告中重新发布了对安进的 “持有” 评级。有两位研究分析师对该股票给予了卖出评级，十位给予了持有评级，十二位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat.com 的数据，安进目前的平均评级为 “持有”，平均目标价为 314.09 美元。</p>
<ul>
<li>安进股票因减肥药数据下跌：反应过度还是合理？</li>
</ul>
<p><strong>阅读我们对安进的最新分析</strong></p>
<h2>安进的内部交易</h2>
<p>在其他安进新闻中，执行副总裁 David M. Reese 在 2 月 19 日的交易中出售了 8,711 股公司的股票。股票以 293.22 美元的平均价格出售，总交易额为 2,554,239.42 美元。出售后，该执行副总裁现在直接拥有 62,147 股公司的股票，价值 18,222,743.34 美元。此次交易使其持股减少了 12.29%。该交易已在向 SEC 的法律文件中披露，可以通过此链接访问。此外，高级副总裁 Nancy A. Grygiel 在 2 月 5 日的交易中出售了 1,589 股公司的股票。股票以 304.47 美元的平均价格出售，总交易额为 483,802.83 美元。交易后，该高级副总裁现在直接拥有 7,210 股公司的股票，价值 2,195,228.70 美元。此次交易使其持股减少了 18.06%。该销售的披露可以在这里找到。在过去的九十天里，内部人士出售了 69,341 股公司股票，价值 20,644,335 美元。公司内部人士持有 0.69% 的公司股票。</p>
<h2>安进股票表现</h2>
<ul>
<li>2 只准备在 2025 年飙升的仿制药股票</li>
</ul>
<p>NASDAQ:AMGN 周三开盘价为 315.63 美元。安进公司的十二个月低点为 253.30 美元，十二个月高点为 346.85 美元。该公司的速动比率为 0.95，流动比率为 1.26，债务与股本比率为 9.62。该股票的 50 日简单移动平均为 278.13 美元，200 日简单移动平均为 300.16 美元。该公司的市值为 1695.6 亿美元，市盈率为 41.81，市盈增长比率为 2.63，贝塔值为 0.56。</p>
<p>安进（NASDAQ:AMGN - 获取免费报告）最近在 2 月 4 日发布了季度财报。这家医疗研究公司报告每股收益为 5.31 美元，超出分析师一致预期的 5.04 美元，超出幅度为 0.27 美元。安进的净利润率为 12.24%，股本回报率为 176.32%。分析师预计安进公司在当前财政年度将发布 20.62 的每股收益。</p>
<h2>安进增加股息</h2>
<p>该公司最近还宣布了一项季度股息，将于 3 月 7 日（星期五）支付。2 月 14 日（星期五）的股东将获得每股 2.38 美元的股息。这相当于年化股息 9.52 美元，股息收益率为 3.02%。该股息的除息日为 2 月 14 日（星期五）。这比安进之前的季度股息 2.25 美元有所增加。安进目前的派息比率为 126.09%。</p>
<h2>关于安进</h2>
<p>（免费报告）</p>
<p>安进公司在全球范围内发现、开发、生产和交付人用治疗药物。公司的主要产品包括用于治疗斑块型银屑病、类风湿性关节炎和银屑病关节炎的恩利昔；用于治疗成年斑块型银屑病、银屑病关节炎和与贝赫切特病相关的口腔溃疡的 Otezla；用于治疗绝经后女性骨质疏松症的 Prolia；用于预防骨骼相关事件的 XGEVA；可降低心肌梗死、中风和冠状动脉再血管化风险的 Repatha；用于治疗免疫性血小板减少症患者的 Nplate；用于治疗复发性或难治性多发性骨髓瘤患者的 KYPROLIS；用于治疗红细胞数量低于正常水平和贫血的 Aranesp；用于治疗绝经后男性和女性骨质疏松症的 EVENITY；用于治疗野生型 RAS 转移性结直肠癌患者的 Vectibix；用于治疗急性淋巴细胞白血病患者的 BLINCYTO；用于治疗甲状腺眼病的 TEPEZZA；以及用于治疗慢性难治性痛风的 KRYSTEXXA。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过安进</li>
<li>ETF 会支付股息吗？你需要知道的事项</li>
<li>Tempus AI 是一个买入机会，如果你能承受波动性</li>
<li>股票情绪分析：它是如何工作的</li>
<li>大规模回购：三只向股东返还大量现金的股票</li>
<li>三个股票代码引领迷因股复兴</li>
<li>Nebius 财报后下滑：长期买入机会？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>此即时新闻提醒是由叙事科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在安进吗？</h2>
<p>在你考虑安进之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而安进并不在名单上。</p>
<p>虽然安进目前在分析师中被评为 “持有” 评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>在这里查看这五只股票</p>

安进

<p>红鹤财富管理公司（Red Crane Wealth Management LLC）在第四季度通过购买 1,975 股，获得了价值约 515,000 美元的安进（Amgen Inc.，NASDAQ:AMGN）新头寸。其他机构投资者，包括 Talbot Financial LLC 和瑞士国家银行（Swiss National Bank），也增加了对安进的持股。分析师对该股票的评级不一，平均目标价为 314.09 美元。安进的股票表现显示，过去十二个月的价格区间在 253.30 美元到 346.85 美元之间，目前市值为 1695.6 亿美元</p>

<p>Red Crane Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The fund bought 1,975 shares of the medical research company's stock, valued at approximately $515,000.</p>
<div class="lb-trans"><p>红鹤财富管理公司在第四季度购买了安进公司（NASDAQ:AMGN - 免费报告）股票的新头寸，根据其最近向证券交易委员会提交的 13F 文件。该基金购买了 1,975 股这家医疗研究公司的股票，价值约为 515,000 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 12/2 - 12/6</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 12/2 - 12/6</li>
</ul>
</div><p>Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Talbot Financial LLC boosted its stake in shares of Amgen by 5.6% during the 4th quarter. Talbot Financial LLC now owns 42,791 shares of the medical research company's stock worth $11,153,000 after acquiring an additional 2,274 shares during the period. Swiss National Bank boosted its position in Amgen by 0.3% during the third quarter. Swiss National Bank now owns 1,592,233 shares of the medical research company's stock worth $513,033,000 after purchasing an additional 5,500 shares during the period. Asset Advisors Investment Management LLC increased its holdings in shares of Amgen by 9.0% in the third quarter. Asset Advisors Investment Management LLC now owns 35,934 shares of the medical research company's stock valued at $11,578,000 after purchasing an additional 2,954 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of Amgen by 6.0% in the third quarter. Principal Financial Group Inc. now owns 635,172 shares of the medical research company's stock valued at $204,659,000 after purchasing an additional 35,785 shares during the period. Finally, Ascent Wealth Partners LLC lifted its stake in shares of Amgen by 0.7% during the 4th quarter. Ascent Wealth Partners LLC now owns 9,024 shares of the medical research company's stock worth $2,352,000 after buying an additional 64 shares during the last quarter. 76.50% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也增加或减少了对该公司的持股。Talbot Financial LLC 在第四季度将其在安进的股份增加了 5.6%。Talbot Financial LLC 现在拥有 42,791 股这家医疗研究公司的股票，价值 11,153,000 美元，此前在此期间又购买了 2,274 股。瑞士国家银行在第三季度将其在安进的持股增加了 0.3%。瑞士国家银行现在拥有 1,592,233 股这家医疗研究公司的股票，价值 513,033,000 美元，此前在此期间又购买了 5,500 股。资产顾问投资管理公司在第三季度将其在安进的持股增加了 9.0%。资产顾问投资管理公司现在拥有 35,934 股这家医疗研究公司的股票，价值 11,578,000 美元，此前在上个季度又购买了 2,954 股。Principal Financial Group Inc.在第三季度将其在安进的持股增加了 6.0%。Principal Financial Group Inc.现在拥有 635,172 股这家医疗研究公司的股票，价值 204,659,000 美元，此前在此期间又购买了 35,785 股。最后，Ascent Wealth Partners LLC 在第四季度将其在安进的持股增加了 0.7%。Ascent Wealth Partners LLC 现在拥有 9,024 股这家医疗研究公司的股票，价值 2,352,000 美元，此前在上个季度又购买了 64 股。76.50% 的股票由机构投资者持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>AMGN has been the topic of a number of research reports. Jefferies Financial Group reiterated a &#34;buy&#34; rating and issued a $380.00 price target on shares of Amgen in a research note on Tuesday, November 12th. Wolfe Research started coverage on Amgen in a research report on Friday, November 15th. They issued a &#34;peer perform&#34; rating on the stock. Redburn Partners dropped their price target on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Citigroup reaffirmed a &#34;neutral&#34; rating on shares of Amgen in a report on Wednesday, February 5th. Finally, UBS Group reissued a &#34;hold&#34; rating on shares of Amgen in a report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Amgen currently has an average rating of &#34;Hold&#34; and an average price target of $314.09.</p>
<div class="lb-trans"><p>安进一直是多份研究报告的主题。杰富瑞金融集团在 11 月 12 日的研究报告中重申了对安进的 “买入” 评级，并给出了 380.00 美元的目标价。沃尔夫研究在 11 月 15 日的研究报告中开始覆盖安进，并对该股票给予了 “同行表现” 的评级。Redburn Partners 在 11 月 27 日的报告中将安进的目标价从 200.00 美元下调至 195.00 美元。花旗集团在 2 月 5 日的报告中重申了对安进的 “中性” 评级。最后，瑞银集团在 2 月 12 日的报告中重新发布了对安进的 “持有” 评级。有两位研究分析师对该股票给予了卖出评级，十位给予了持有评级，十二位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat.com 的数据，安进目前的平均评级为 “持有”，平均目标价为 314.09 美元。</p>
</div><ul>
<li>Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?</li>
</ul>
<div class="lb-trans"><ul>
<li>安进股票因减肥药数据下跌：反应过度还是合理？</li>
</ul>
</div><p><strong>Read Our Latest Analysis on Amgen</strong></p>
<div class="lb-trans"><p><strong>阅读我们对安进的最新分析</strong></p>
</div><h2>Insider Transactions at Amgen</h2>
<div class="lb-trans"><h2>安进的内部交易</h2>
</div><p>In other Amgen news, EVP David M. Reese sold 8,711 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the sale, the executive vice president now directly owns 62,147 shares of the company's stock, valued at $18,222,743.34. The trade was a 12.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the firm's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares of the company's stock, valued at $2,195,228.70. The trade was a 18.06 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 69,341 shares of company stock worth $20,644,335. Corporate insiders own 0.69% of the company's stock.</p>
<div class="lb-trans"><p>在其他安进新闻中，执行副总裁 David M. Reese 在 2 月 19 日的交易中出售了 8,711 股公司的股票。股票以 293.22 美元的平均价格出售，总交易额为 2,554,239.42 美元。出售后，该执行副总裁现在直接拥有 62,147 股公司的股票，价值 18,222,743.34 美元。此次交易使其持股减少了 12.29%。该交易已在向 SEC 的法律文件中披露，可以通过此链接访问。此外，高级副总裁 Nancy A. Grygiel 在 2 月 5 日的交易中出售了 1,589 股公司的股票。股票以 304.47 美元的平均价格出售，总交易额为 483,802.83 美元。交易后，该高级副总裁现在直接拥有 7,210 股公司的股票，价值 2,195,228.70 美元。此次交易使其持股减少了 18.06%。该销售的披露可以在这里找到。在过去的九十天里，内部人士出售了 69,341 股公司股票，价值 20,644,335 美元。公司内部人士持有 0.69% 的公司股票。</p>
</div><h2>Amgen Stock Performance</h2>
<div class="lb-trans"><h2>安进股票表现</h2>
</div><ul>
<li>2 Generic Drug Stocks Ready to Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只准备在 2025 年飙升的仿制药股票</li>
</ul>
</div><p>NASDAQ:AMGN opened at $315.63 on Wednesday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The stock's 50-day simple moving average is $278.13 and its 200 day simple moving average is $300.16. The firm has a market capitalization of $169.56 billion, a PE ratio of 41.81, a price-to-earnings-growth ratio of 2.63 and a beta of 0.56.</p>
<div class="lb-trans"><p>NASDAQ:AMGN 周三开盘价为 315.63 美元。安进公司的十二个月低点为 253.30 美元，十二个月高点为 346.85 美元。该公司的速动比率为 0.95，流动比率为 1.26，债务与股本比率为 9.62。该股票的 50 日简单移动平均为 278.13 美元，200 日简单移动平均为 300.16 美元。该公司的市值为 1695.6 亿美元，市盈率为 41.81，市盈增长比率为 2.63，贝塔值为 0.56。</p>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>安进（NASDAQ:AMGN - 获取免费报告）最近在 2 月 4 日发布了季度财报。这家医疗研究公司报告每股收益为 5.31 美元，超出分析师一致预期的 5.04 美元，超出幅度为 0.27 美元。安进的净利润率为 12.24%，股本回报率为 176.32%。分析师预计安进公司在当前财政年度将发布 20.62 的每股收益。</p>
</div><h2>Amgen Increases Dividend</h2>
<div class="lb-trans"><h2>安进增加股息</h2>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Amgen's previous quarterly dividend of $2.25. Amgen's payout ratio is presently 126.09%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 3 月 7 日（星期五）支付。2 月 14 日（星期五）的股东将获得每股 2.38 美元的股息。这相当于年化股息 9.52 美元，股息收益率为 3.02%。该股息的除息日为 2 月 14 日（星期五）。这比安进之前的季度股息 2.25 美元有所增加。安进目前的派息比率为 126.09%。</p>
</div><h2>About Amgen</h2>
<div class="lb-trans"><h2>关于安进</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.</p>
<div class="lb-trans"><p>安进公司在全球范围内发现、开发、生产和交付人用治疗药物。公司的主要产品包括用于治疗斑块型银屑病、类风湿性关节炎和银屑病关节炎的恩利昔；用于治疗成年斑块型银屑病、银屑病关节炎和与贝赫切特病相关的口腔溃疡的 Otezla；用于治疗绝经后女性骨质疏松症的 Prolia；用于预防骨骼相关事件的 XGEVA；可降低心肌梗死、中风和冠状动脉再血管化风险的 Repatha；用于治疗免疫性血小板减少症患者的 Nplate；用于治疗复发性或难治性多发性骨髓瘤患者的 KYPROLIS；用于治疗红细胞数量低于正常水平和贫血的 Aranesp；用于治疗绝经后男性和女性骨质疏松症的 EVENITY；用于治疗野生型 RAS 转移性结直肠癌患者的 Vectibix；用于治疗急性淋巴细胞白血病患者的 BLINCYTO；用于治疗甲状腺眼病的 TEPEZZA；以及用于治疗慢性难治性痛风的 KRYSTEXXA。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Amgen</li>
<li>Do ETFs Pay Dividends? What You Need to Know</li>
<li>Tempus AI Is a Buy, If You Can Handle the Volatility</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>Massive Buybacks: 3 Stocks Returning Big Cash to Shareholders</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过安进</li>
<li>ETF 会支付股息吗？你需要知道的事项</li>
<li>Tempus AI 是一个买入机会，如果你能承受波动性</li>
<li>股票情绪分析：它是如何工作的</li>
<li>大规模回购：三只向股东返还大量现金的股票</li>
<li>三个股票代码引领迷因股复兴</li>
<li>Nebius 财报后下滑：长期买入机会？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒是由叙事科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amgen Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在安进吗？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑安进之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而安进并不在名单上。</p>
</div><p>While Amgen currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然安进目前在分析师中被评为 “持有” 评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

红鹤财富管理有限责任公司在安进公司（NASDAQ:AMGN）持有 51.5 万美元的头寸